文献速递食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病

随机临床试验:Gaviscon Advance与非藻酸盐抗酸剂对肥胖者夜宵后酸袋及餐后反流的抑制效果

Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-28

本研究在肥胖受试者中比较夜宵后单次服用Gaviscon Advance与非藻酸盐抗酸剂对酸袋和餐后反流的抑制效果。结果显示Gaviscon Advance在抑制酸袋中位pH方面优于抗酸剂,且显著减少下食管pH<4时间百分比、症状频率和VAS评分。

要点

  • Gaviscon Advance抑制酸袋中位pH优于非藻酸盐抗酸剂(所有P<0.04)。
  • Gaviscon Advance显著降低下食管pH<4时间百分比、症状频率和VAS(均P<0.05)。
  • 下食管中位pH的抑制在两组间未显示差异。

核心结论

  • 在肥胖个体中,Gaviscon Advance在夜宵后抑制酸袋方面优于非藻酸盐抗酸剂。

研究设计与样本

  • 随机对照试验,26名肥胖受试者随机接受Gaviscon Advance(n=13)或非藻酸盐抗酸剂(n=13)单次夜宵后(晚10点)给药。

主要发现

  • Gaviscon Advance组酸袋中位pH受抑制,优于抗酸剂组(所有P<0.04)。
  • 下食管中位pH的抑制在两组间未显示差异。
  • Gaviscon Advance组下食管pH<4时间百分比、症状频率和VAS评分在第2天较第1天显著降低(均P<0.05),抗酸剂组无显著变化。

临床怎么用

  • 对于肥胖且夜宵后易出现反流的患者,可考虑使用藻酸盐类药物如Gaviscon Advance以减少酸袋和餐后反流。

局限性

  • 样本量较小(共26例),可能影响结果的普遍性。
  • 仅评估单次夜宵后给药效果,未涉及长期使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Late-night supper increases the risk of postprandial reflux from the acid pocket especially in obesity. An alginate-based, raft-forming medication may be useful for obese patients with GERD. AIMS: To compare the efficacy of Gaviscon Advance (Reckitt Benckiser, UK) and a non-alginate antacid in post-supper suppression of the acid pocket and post-prandial reflux among obese participants. METHODS: Participants underwent 48 h wireless and probe-based pH-metry recording of the acid pocket and lower oesophagus, respectively, and were randomised to single post-supper (10 pm) dose of either Gaviscon Advance or a non-alginate antacid on the second night. Primary outcomes were suppression of median pH of acid pocket and lower oesophagus, measured every 10-minutes post-supper for 1 h. Secondary outcomes were suppression of % time pH < 4 at lower oesophagus and improvement in frequency and visual analogue score (VAS) of regurgitation. RESULTS: Of the 81 screened participants, 55 were excluded and 26 (mean age 33.5 years, males 77.8% and BMI 32.8 kg/m2 ) were randomised to Gaviscon Advance (n = 13) or antacid (n = 13). Median pH of the acid pocket but not the lower oesophagus was suppressed with Gaviscon Advance vs antacid (all P < 0.04) Gaviscon Advance but not antacid significantly reduced in % time pH < 4, symptom frequency and VAS on day 2 vs day 1 (all P < 0.05). CONCLUSIONS: Among obese individuals, Gaviscon Advance was superior to a non-alginate antacid in post-supper suppression of the acid pocket. (Clinical trial registration unique identifier: NCT03516188).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Deraman MA, Abdul Hafidz MI, Lawenko RM, et al. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper. Aliment Pharmacol Ther. 2020. PMID: 32343001. doi:10.1111/apt.15746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。